stockrowABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023.
- Revenue
- +66,233.3%
- EPS
- +76.9%
- Free cash flow
- +72.7%
Quarter to June 2026, against a year earlier
Follow ABVC
Alert me
ABVC BioPharma, Inc. (ABVC) EV/Sales
As of 6 November 2026, ABVC BioPharma, Inc. (ABVC) trades at a EV/Sales of 20.6×. Over the past ten years it has ranged from 0.0× (June 2018) to 66,486× (January 2019); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 15.3× | (70.15%) |
| FY2023 | 51.3× | 132.57% |
| FY2022 | 22.1× | (90.34%) |
| FY2021 | 229× | 9.51% |
| FY2020 | 209× | 90.24% |
| FY2019 | 110× | (99.83%) |
| FY2018 | 63,320× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 55.4× | 261.20% |
| Dec 2024 | 15.3× | (29.59%) |
| Sep 2024 | 21.8× | (75.17%) |
| Jun 2024 | 87.7× | (86.15%) |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.7× |
| ACET Adicet Bio, Inc. compare | −2.2× |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | 0.4× |
| BYSI BeyondSpring Inc. compare | 15.4× |
| ABVC ABVC BioPharma, Inc. | 20.6× |
| CVM Cel-Sci Corporation compare | 27.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)